This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
British Journal of Cancer Open Access 27 November 2023
-
A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics
Nature Communications Open Access 13 November 2023
-
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
Genome Biology Open Access 23 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout


References
Nosengo, N. Nature 534, 314–316 (2016).
Hay, M., Thomas, D.W., Craighead, J.L., Economides, C. & Rosenthal, J. Nat. Biotechnol. 32, 40–51 (2014).
Goldstein, I. et al. N. Engl. J. Med. 338, 1397–1404 (1998).
Palumbo, A. et al. Blood 111, 3968–3977 (2008).
Lamb, J. et al. Science 313, 1929–1935 (2006).
Yu, C. et al. Nat. Biotechnol. 34, 419–423 (2016).
Huang, R. et al. Sci. Transl. Med. 3, 80ps16 (2011).
Law, V. et al. Nucleic Acids Res. 42, D1091–D1097 (2014).
Qin, C. et al. Nucleic Acids Res. 42, D1118–D1123 (2014).
Mi, H. et al. Nucleic Acids Res. 33, D284–D288 (2005).
Blaxill, Z., Holland-Crimmin, S. & Lifely, R. J. Biomol. Screen. 14, 547–556 (2009).
Lawrence, M.S. et al. Nature 505, 495–501 (2014).
Heller, S.R., McNaught, A., Pletnev, I., Stein, S. & Tchekhovskoi, D. J. Cheminform. 7, 23 (2015).
Acknowledgements
We thank the members of the Broad Institute Compound Management team for their invaluable assistance. We also thank C. Yu, J. Boehm, N. Tolliday, J. Athanasopoulos, J. Rosains, S. Loranger, and A. Burgin for helpful scientific discussions. This work was supported in part by NIH LINCS Program grants 3U54 HG006093 (T.R.G. and A.S.), U54 HL127366 (T.R.G. and A.S.), and U54 HG008699 (T.R.G. and A.S.). Additional support was provided by the Howard Hughes Medical Institute (T.R.G.), NIH training grant T32 CA009172 (S.M.C.), KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health) Award KL2 TR001100 (S.M.C.), and the Conquer Cancer Foundation of ASCO Young Investigator Award (S.M.C.).
Author information
Authors and Affiliations
Contributions
S.M.C. and T.R.G. conceived the project, designed experiments, and wrote the paper with input from coauthors; A.V., S.E.J., P.M., and J.A.B. performed analytical chemistry and compound management activities; P.M., J.A.B., and S.M.C. performed chemical-structure analysis; S.M.C., Z.L., J.E.H., R.N., and C.C.M. annotated drug properties; B.W. and M.K. designed the Drug Repurposing Hub web-portal interface and assisted with manuscript figures; J.G., J.A., and A.S. designed and implemented the hub database, interactive web platform, and data API.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Figures & Tables
Supplementary Figures 1–6 & Supplementary Tables 1–4 (PDF 13309 kb)
Rights and permissions
About this article
Cite this article
Corsello, S., Bittker, J., Liu, Z. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med 23, 405–408 (2017). https://doi.org/10.1038/nm.4306
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4306
This article is cited by
-
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion
Molecular Medicine (2023)
-
Benchmarking causal reasoning algorithms for gene expression-based compound mechanism of action analysis
BMC Bioinformatics (2023)
-
On the correspondence between the transcriptomic response of a compound and its effects on its targets
BMC Bioinformatics (2023)
-
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
Genome Biology (2023)
-
Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii
Nature Chemical Biology (2023)